Summary
DRUGS firm Shire is teaming up with GlaxoSmithKline to market its attention-deficit drug Vyvanse.
The three-year deal will see the pair target the adult market, which is a relatively untapped source of new sales that could possibly rake in another Pounds 350m of annual revenues.See the full content of this document
Extract
Shire Teams with Gsk On Vyvanse
Vyvanse is a key product f...
See the full content of this document
Sponsored links
